Pulchinenoside B4 Inhibits NLRP3 Inflammasome in Colitis via CD1d Targeting

Study Background and Research Question

Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease characterized by mucosal ulcers, diarrhea, and rectal bleeding. Its global prevalence is rising, partly due to environmental and lifestyle changes. Despite advances in immunosuppressive and anti-inflammatory therapies, current UC treatments are often limited by side effects and incomplete disease control. A critical driver of UC pathogenesis is the activation of the mucosal immune system, particularly through macrophage-driven inflammatory signaling and the release of pro-inflammatory cytokines. Among these, the NLRP3 inflammasome—a multiprotein complex activated in macrophages—has emerged as a pivotal mediator of intestinal inflammation and tissue injury. The priming phase of NLRP3 activation is largely governed by the NF-κB signaling pathway, which upregulates transcription of inflammasome components such as NLRP3 itself, pro-IL-1β, and IL-18.

The reference study (Li et al., 2025) investigates whether Pulchinenoside B4 (PB4), a triterpenoid saponin derived from traditional medicinal plants, can alleviate experimental colitis by modulating the NLRP3 inflammasome in macrophages. The central research question is whether PB4 exerts its anti-colitic effects by targeting upstream regulators of NLRP3 activation, with a focus on the CD1d molecule and the AKT-STAT1-PRDX1-NF-κB axis.

Key Innovation from the Reference Study

The main innovation lies in the identification of CD1d—a non-classical MHC molecule involved in glycolipid antigen presentation—as a novel target of PB4 in intestinal macrophages. The study is among the first to demonstrate that PB4 mediates its anti-inflammatory effects by inhibiting CD1d-dependent activation of the NLRP3 inflammasome, thereby reducing downstream inflammatory signaling in UC. Mechanistically, PB4 disrupts the AKT-STAT1-PRDX1-NF-κB pathway, highlighting a new molecular bridge between plant-derived agents, innate immune regulation, and inflammasome biology. These findings suggest that targeting the CD1d/NLRP3 axis could enable more selective and durable control of intestinal inflammation, paving the way for future clinical translation of PB4-based or analogous therapies.

Methods and Experimental Design Insights

The experimental framework integrates both in vivo and in vitro approaches to dissect the role of PB4 in colitis and inflammasome activation:

• DSS-Induced Colitis Model: C57BL/6 mice were administered dextran sodium sulfate (DSS) to induce acute colitis, a widely accepted model that recapitulates key features of human UC.
• Genetic Controls: The study utilized NLRP3 knockout (NLRP3−/−) mice and macrophage-specific CD1d-deficient (CD1d−/−) models to parse the dependence of PB4's effects on these pathways.
• Cellular Assays: Mouse intestinal macrophages and epithelial cells were isolated and exposed to PB4. LPS-induced macrophages served as a system to study NF-κB and inflammasome responses in vitro.
• Target Engagement: Biolayer interferometry (BLI) and cellular thermal shift assays (CETSA) confirmed the direct interaction between PB4 and its molecular targets.
• Inflammatory Readouts: Cytokine profiles (IL-1β, IL-6), inflammasome components (NLRP3, ASC, Caspase-1), and histopathological analysis were used to quantify inflammation and tissue injury.

Protocol Parameters

• DSS-induced colitis induction: Administer 2-3% DSS in drinking water for 5–7 days to model acute colitis in C57BL/6 mice.
• PB4 administration: Dosage and route optimized per experimental design; refer to the original study for specifics.
• Use of knockout models: Employ NLRP3−/− and CD1d−/− mice to dissect pathway dependence.
• LPS stimulation in vitro: Expose primary macrophages to 100 ng/mL LPS to prime NF-κB signaling before PB4 treatment.
• Target validation: Apply BLI and CETSA to confirm small molecule–protein interactions.

Core Findings and Why They Matter

Pulchinenoside B4 robustly attenuated DSS-induced colitis severity in wild-type mice, as evidenced by reduced disease activity index, less mucosal ulceration, and lower levels of pro-inflammatory cytokines. The anti-colitic effect was lost in NLRP3−/− mice, establishing NLRP3 as a critical mediator. Importantly, PB4 selectively inhibited NLRP3 inflammasome activation in intestinal macrophages, but not in epithelial cells, indicating cell-type specificity. Mechanistic investigations revealed that PB4 binds to CD1d, a molecule upregulated during colitis, and this interaction suppresses activation of the downstream AKT-STAT1-PRDX1-NF-κB signaling pathway. This, in turn, prevents the transcriptional upregulation required for NLRP3 inflammasome assembly and pro-inflammatory cytokine production. Macrophage-specific CD1d deficiency abolished PB4's protective effects, confirming the necessity of this target.

These findings illuminate a new therapeutic axis—CD1d/AKT-STAT1/PRDX1/NF-κB/NLRP3—that can be modulated by plant-derived small molecules. Such selectivity offers a promising alternative to broad immunosuppression, with the potential for fewer systemic side effects and more precise control of gut inflammation.

Comparison with Existing Internal Articles

The mechanistic insights from this study align with, yet extend beyond, what has been established using pharmacological NF-κB inhibitors such as JSH-23. Internal resources—such as "JSH-23: Unraveling NF-κB Inhibition for Precision Inflammation Research" and "JSH-23: Precision NF-κB Inhibitor for Advanced Inflammation Research"—highlight the utility of JSH-23 in dissecting the NF-κB signaling pathway and its specific blockade of p65 nuclear translocation. JSH-23 is shown to inhibit pro-inflammatory cytokine expression in LPS-stimulated macrophages and in vivo inflammation models, such as cisplatin-induced acute kidney injury. However, while JSH-23 offers a direct, well-characterized means of inhibiting NF-κB transcriptional activity, the PB4 study introduces a novel upstream regulatory node (CD1d) that modulates NF-κB–dependent NLRP3 activation.

Both research lines emphasize the critical role of NF-κB in priming inflammasome activation and demonstrate the value of small molecule inhibitors for inflammation research. PB4's action through CD1d provides an additional layer of mechanistic control, potentially allowing for greater specificity in targeting macrophage-driven inflammation in colitis.

Limitations and Transferability

While the study offers compelling evidence for PB4's efficacy and mechanistic specificity in murine models, several limitations remain. First, the translation of findings from DSS-induced colitis in mice to human IBD may be impacted by species differences in immune regulation and drug metabolism. Second, the use of genetic knockout models clarifies pathway dependence but may not fully recapitulate the complexity of human disease. Third, while PB4 targets CD1d and modulates NF-κB signaling, off-target effects and long-term safety have yet to be explored. Finally, the therapeutic window, dosing regimen, and potential for combination therapy with existing standards of care require further investigation before clinical application.

Transferability to other models of inflammation (e.g., kidney injury, systemic sepsis) is plausible given the centrality of NF-κB and NLRP3 pathways, but should be empirically validated. Small molecule NF-κB inhibitors like JSH-23 have demonstrated such cross-model relevance, as documented in internal studies, which supports the potential for workflow adaptation.

Research Support Resources

For researchers aiming to dissect NF-κB–dependent inflammasome activation in macrophages or to model pro-inflammatory cytokine inhibition, robust chemical tools are essential. JSH-23 (SKU B1645) is a validated small molecule NF-κB inhibitor that blocks p65 nuclear translocation without affecting IκB degradation, enabling precise study of NF-κB signaling and downstream effects in both in vitro and in vivo models. APExBIO provides detailed product specifications and usage guidelines, supporting reproducible inflammation research and facilitating the exploration of pathways highlighted by recent advances such as the PB4–CD1d–NLRP3 axis.